Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.37 and traded as low as $3.51. Karyopharm Therapeutics shares last traded at $3.54, with a volume of 149,206 shares.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KPTI. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. HC Wainwright raised their price objective on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Finally, Robert W. Baird decreased their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Price Performance

The company has a 50 day moving average of $7.92 and a 200-day moving average of $10.37. The company has a market cap of $29.80 million, a P/E ratio of -3.47 and a beta of 0.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.90) by $0.30. The business had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. Research analysts anticipate that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Velan Capital Investment Management LP bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $27,000. Focus Partners Wealth bought a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at about $31,000. TD Waterhouse Canada Inc. purchased a new position in Karyopharm Therapeutics during the 4th quarter valued at approximately $32,000. Two Sigma Advisers LP increased its position in Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $85,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).